BOTOX® Cosmetic

Компания Allergan Aesthetics объявила, что Комитет по медицинским продуктам для человека (CHMP) Европейского агентства по лекарственным средствам принял положительное мнение о Boey® (trenibotulinumtoxinE) для временного улучшения внешнего вида умеренных и тяжелых линий между бровями у взрослых. Этот продукт может стать первым ботулотоксином серотипа E, доступным для взрослых пациентов.

AbbVie released its financial results for Q1 2026, reporting a net revenue of $15 billion, which is a 12.4% increase over the previous year. Global revenue from Botox Cosmetic was $668 million, marking a 20.2% increase.

AbbVie announced that it has received a Complete Response from the FDA regarding its biological license application for TrenibotulinumtoxinE (TrenibotE). The FDA has requested additional information on manufacturing processes but did not impose any requirements for additional clinical studies.

BOTOX® Cosmetic continues to support women entrepreneurs through the 'The Confidence Collective' program launched this year. The program provides access to resources, coaching, and funding, along with $20,000 in awards for twenty participants.

BOTOX® Cosmetic has launched 'The Confidence Collective' initiative aimed at supporting women entrepreneurs. Since 2023, the program has allocated $1.2 million in grants for winners to help them grow their businesses. Applications are accepted until April 29, 2026.

Allergan Aesthetics has announced the opening of a new AMI training center in Austin, Texas, which is the third center in the United States opened in the past year. The center offers in-depth training and hands-on preparation for medical professionals in the aesthetics field, including injection techniques and complications management.

Allergan Aesthetics, part of AbbVie, has announced the opening of a new AMI training center in Austin, Texas. This center offers advanced training for aesthetic professionals, including injection techniques, complication management, and practice development.

Allergan Aesthetics, part of AbbVie, will present 21 scientific electronic posters at the World Congress of Aesthetic and Anti-Aging Medicine in Monaco, highlighting the company's leadership in patient-centered innovations. The data presented supports the efficacy and safety of BOTOX® Cosmetic, which continues to show a high level of patient satisfaction.

Allergan Aesthetics has presented the results of a global study showing that patient expectations in medical aesthetics are evolving. A new approach to multimodal treatment and educational solutions that help professionals better meet patient needs will be presented at the AMWC 2026 congress in Monaco.

Allergan Aesthetics has introduced the Skin Quality Index, a unified terminology to standardize discussions about skin quality between patients and physicians. This innovation aims to improve communications and support more informed aesthetic consultations.